Roy S Gardner

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5646545/publications.pdf

Version: 2024-02-01

66 papers	7,908 citations	304602 22 h-index	123376 61 g-index
67 all docs	67 docs citations	67 times ranked	5488 citing authors

#	Article	IF	Citations
1	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	2.9	820
2	Reducing the electrogram review burden imposed by insertable cardiac monitors. Journal of Cardiovascular Electrophysiology, 2022, 33, 741-750.	0.8	3
3	Realâ€world evidence in a national health service: results of the UK CardioMEMS HF System Postâ€Market Study. ESC Heart Failure, 2022, 9, 48-56.	1.4	28
4	The â€˜Ten Commandmentsâ€™ of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2022, 43, 440-441.	1.0	95
5	GuÃa ESC 2021 sobre el diagnÃ³stico y tratamiento de la insuficiencia cardiaca aguda y crÃ³nica. Revista Espanola De Cardiologia, 2022, 75, 523.e1-523.e114.	0.6	40
6	Chronic heart failure: epidemiology, investigation and management. Medicine, 2022, , .	0.2	0
7	Adherence to prescribed medications in patients with heart failure: insights from liquid chromatographyâ€“tandem mass spectrometry-based urine analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 296-301.	1.4	12
8	Realâ€world outcomes in cardiac resynchronization therapy patients: design and baseline demographics of the SMARTâ€Registry. ESC Heart Failure, 2021, 8, 1675-1680.	1.4	7
9	Multiparameter diagnostic sensor measurements during clinically stable periods and worsening heart failure in ambulatory patients. ESC Heart Failure, 2021, 8, 1571-1581.	1.4	13
10	Multiparameter diagnostic sensor measurements in heart failure patients presenting with SARSâ€CoVâ€2 infection. ESC Heart Failure, 2021, 8, 4026-4036.	1.4	5
11	Pharmacological secondary prevention of MI. The Prescriber, 2021, 32, 13-20.	0.1	0
12	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	1.0	5,558
13	Ambulatory Monitoring of Heart Sounds via an Implanted Device Is Superior to Auscultation for Prediction of Heart Failure Events. Journal of Cardiac Failure, 2020, 26, 151-159.	0.7	21
14	Anticoagulation therapy in heart failure and sinus rhythm: a systematic review and meta-analysis. Heart, 2019, 105, 1325-1334.	1.2	24
15	Ferumoxytol-enhanced MRI in patients with prior cardiac transplantation. Open Heart, 2019, 6, e001115.	0.9	2
16	Performance of the LumiraDx Platform INR Test in an Anticoagulation Clinic Point-of-Care Setting Compared With an Established Laboratory Reference Method. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961989042.	0.7	2
17	Thirty years of heart failure. European Heart Journal, 2018, 39, 824-826.	1.0	2
18	Who needs an implantable cardioverterâ€defibrillator? Controversies and opportunities after DANISH. European Journal of Heart Failure, 2018, 20, 413-416.	2.9	10

#	Article	IF	Citations
19	Ferumoxytol-enhanced magnetic resonance imaging in acute myocarditis. Heart, 2018, 104, 300-305.	1.2	24
20	Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. Heart, 2018, 104, 144-150.	1.2	61
21	Who Benefits From a Defibrillatorâ€"Balancing the Risk of Sudden Versus Non-sudden Death. Current Heart Failure Reports, 2018, 15, 376-389.	1.3	5
22	Which patients with heart failure should receive specialist palliative care?. European Journal of Heart Failure, 2018, 20, 1338-1347.	2.9	60
23	HeartLogic Multisensor Algorithm Identifies Patients During Periods of Significantly Increased Risk of Heart Failure Events. Circulation: Heart Failure, 2018, 11, e004669.	1.6	73
24	Haemodynamic monitoring of cardiac status using heart sounds from an implanted cardiac device. ESC Heart Failure, 2017, 4, 605-613.	1.4	17
25	Ferumoxytol-enhanced magnetic resonance imaging methodology and normal values at 1.5 and 3T. Journal of Cardiovascular Magnetic Resonance, 2016, 18, 46.	1.6	20
26	The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. European Journal of Heart Failure, 2016, 18, 1491-1498.	2.9	54
27	Use of direct oral anticoagulants in thromboembolic disease. The Prescriber, 2016, 27, 15-22.	0.1	2
28	Palliative care needs in patients hospitalized with heart failure (PCHF) study: rationale and design. ESC Heart Failure, 2015, 2, 25-36.	1.4	21
29	The Emerging Potential of the Apelin-APJ System in Heart Failure. Journal of Cardiac Failure, 2015, 21, 489-498.	0.7	43
30	Combined Free Light Chains Are Novel Predictors of Prognosis in Heart Failure. JACC: Heart Failure, 2015, 3, 618-625.	1.9	18
31	Falling Cardiovascular Mortality in HeartÂFailure With Reduced Ejection Fraction and Implications for Clinical Trials. JACC: Heart Failure, 2015, 3, 603-614.	1.9	36
32	Clinical characteristics and outcomes of patients with angina and heart failure in the <scp>CHARM</scp> (Candesartan in Heart Failure Assessment of Reduction in Mortality and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 217	2.9	17
33	When to consider an implantable cardioverter defibrillator following myocardial infarction?. Heart, 2015, 101, 1996-2000.	1.2	2
34	Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina. Circulation: Heart Failure, 2015, 8, 717-724.	1.6	22
35	Biomarkers of acute rejection following cardiac transplantation. Biomarkers in Medicine, 2014, 8, 815-832.	0.6	10
36	Interventricular lead separation is critical for NT-proBNP reduction after cardiac resynchronization therapy. Biomarkers in Medicine, 2014, 8, 797-806.	0.6	1

#	Article	IF	Citations
37	Do plasma concentrations of apelin predict prognosis in patients with advanced heart failure?. Biomarkers in Medicine, 2014, 8, 807-813.	0.6	7
38	Biomarkers in mechanical circulatory support. Biomarkers in Medicine, 2014, 8, 855-869.	0.6	1
39	The ease of use and reproducibility of the Alereâ„¢ Heart Check System: a comparison of patient and healthcare professional measurement of BNP. Biomarkers in Medicine, 2014, 8, 791-796.	0.6	14
40	Bridging to Heart Transplantation with 128 Days of Intra-aortic Balloon Pump Support. American Journal of Medicine, 2014, 127, e9-e10.	0.6	3
41	Heart Failure Association of the <scp>European Society of Cardiology</scp> Specialist Heart Failure Curriculum. European Journal of Heart Failure, 2014, 16, 151-162.	2.9	52
42	Emerging biomarkers for heart failure: an update. Biomarkers in Medicine, 2014, 8, 833-840.	0.6	4
43	LGE and NT-proBNP Identify LowÂRisk of Death or Arrhythmic Events inÂPatients With Primary Prevention ICDs. JACC: Cardiovascular Imaging, 2014, 7, 561-569.	2.3	26
44	Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). European Heart Journal, 2014, 35, 3426-3433.	1.0	18
45	Nongenetic markers in heart failure. Biomarkers in Medicine, 2014, 8, 773-775.	0.6	0
46	Ventricular Assist Devices as Rescue Therapy in Cardiogenic Shock After Subarachnoid Hemorrhage. Annals of Thoracic Surgery, 2014, 97, 1440-1443.	0.7	3
47	Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). European Heart Journal, 2014, 35, 2714-2721.	1.0	71
48	Spectral microvolt T-wave alternans testing has no prognostic value in patients recently hospitalized with decompensated heart failure. European Journal of Heart Failure, 2013, 15, 1253-1261.	2.9	12
49	Deactivation of implantable cardioverterâ€“defibrillators at end of life. Future Cardiology, 2013, 9, 885-896.	0.5	2
50	ICDs in end-stage heart failure. BMJ Supportive and Palliative Care, 2012, 2, 94-97.	0.8	16
51	The hazards of brussels sprouts consumption at Christmas. Medical Journal of Australia, 2012, 197, 661-662.	0.8	4
52	UK guidelines for referral and assessment of adults for heart transplantation. Heart, 2011, 97, 1520-1527.	1.2	99
53	An update on peripartum cardiomyopathy. Expert Review of Cardiovascular Therapy, 2011, 9, 1155-1160.	0.6	7
54	Novel biomarkers in heart failure: an overview. Biomarkers in Medicine, 2009, 3, 453-463.	0.6	8

#	Article	IF	Citations
55	The reign of the natriuretic peptides in patients with heart failure continues. Biomarkers in Medicine, 2008, 2, 437-439.	0.6	2
56	A change in N-terminal pro-brain natriuretic peptide is predictive of outcome in patients with advanced heart failure. European Journal of Heart Failure, 2007, 9, 266-271.	2.9	34
57	Renal dysfunction, as measured by the modification of diet in renal disease equations, and outcome in patients with advanced heart failure. European Heart Journal, 2007, 28, 3027-3033.	1.0	30
58	B-type natriuretic peptides in heart failure. Biomarkers in Medicine, 2007, 1, 243-250.	0.6	7
59	Emerging role of the apelin system in cardiovascular homeostasis. Biomarkers in Medicine, 2007, 1, 37-43.	0.6	5
60	Can we use B-type natriuretic peptides to monitor patients with heart failure?. Biomarkers in Medicine, 2007, 1, 349-353.	0.6	0
61	Who needs a heart transplant?The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. European Heart Journal, 2006, 27, 770-772.	1.0	16
62	The Modification of Diet in Renal Disease (MDRD) equations provide valid estimations of glomerular filtration rates in patients with advanced heart failure. European Journal of Heart Failure, 2006, 8, 63-67.	2.9	113
63	Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. European Journal of Heart Failure, 2006, 8, 355-360.	2.9	174
64	The prognostic value of anemia, right-heart catheterization and neurohormones in chronic heart failure. Expert Review of Cardiovascular Therapy, 2006, 4, 51-57.	0.6	3
65	N-terminal brain natriuretic peptide is a more powerful predictor of mortality than endothelin-1, adrenomedullin and tumour necrosis factor-Î± in patients referred for consideration of cardiac transplantation. European Journal of Heart Failure, 2005, 7, 253-260.	2.9	29
66	N-Terminal Brain Natriuretic Peptide, But Not Anemia, Is a Powerful Predictor of Mortality in Advanced Heart Failure. Journal of Cardiac Failure, 2005, 11, S47-S53.	0.7	21